The American Society of Clinical Oncology (ASCO) today issued a set of recommendations for overcoming financial barriers to patient participation in cancer clinical trials. ASCO’s policy statement, “Addressing Financial Barriers to Patient Participation in Clinical Trials,” stresses the importance of increasing participation in clinical research, especially for patients from particular ethnic/racial, geographic, age, socioeconomic, and other underserved demographic subgroups.
Senator John McCain will lie in state in the U.S. Capitol Building today. The following ASCO statement pays tribute to his life-long service to our country.
Alexandria, Va. —In a new position statement, the American Society of Clinical Oncology (ASCO) warns that some of the practices of pharmacy benefit manager (PBM) companies use could hinder patient access to timely, high-quality cancer care. ASCO describes a range of PBM practices that, while they may be intended to help control costs in cancer care, might compromise physicians’ ability to provide the right treatment at the right time for people with cancer.
Alexandria, VA – Advanced practice providers (APPs) have increasingly become integral members of the oncology care delivery team, according to the first large-scale study of nurse practitioners (NPs) and physician assistants (PAs) in oncology published today in the Journal of Oncology Practice. The “Understanding the Role of Advanced Practice Providers in the U.S.” study was conducted as a collaboration of the American Society of Clinical Oncology (ASCO), the American Academy of PAs (AAPA), the Association of Physician Assistants in Oncology (APAO), the Advanced Practitioner Society for Hematology and Oncology (APSHO), and the Oncology Nursing Society (ONS).
Alexandria, Va. – The American Society of Clinical Oncology (ASCO) warns that Medicaid work requirements may hinder patients’ access to essential cancer care and reduce the already limited time physicians are able to spend with their patients. In a new position statement released today, ASCO also recommends that federal and state policymakers take specific steps to ensure that new Medicaid requirements will not harm patients with cancer.
ASCO strongly opposes the Centers for Medicare & Medicaid Services (CMS) decision to allow Medicare Advantage plans to employ step therapy across physician-administered and self-administered drugs under Medicare Part B and Part D.
ASCO strongly opposes provisions in the 2019 Medicare Physician Fee Schedule (MPFS) proposed rule that could significantly cut cancer care resources that are needed to provide high-quality care to individuals with cancer.
Today at the 2018 ASCO Annual Meeting, National Cancer Institute (NCI) Director Norman Sharpless, MD, announced $10 million in new funding for the National Clinical Trials Network (NCTN). ASCO applauds Dr. Sharpless' leadership in ensuring NCI's continued commitment to clinical trials, which expand our knowledge of cancer and offer the best treatment options for many patients.
As nearly 40,000 oncology professionals from around the world gather in Chicago for the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) to learn about the latest in clinical cancer research -- from new treatment options and advances in precision medicine to insight for improving access to care -- ASCO welcomes the U.S. Food and Drug Administration's (FDA) announcement that it is advancing new policies to make the drug review and approval process more modern, more scientifically rigorous, and more efficient.
The American Society of Clinical Oncology (ASCO) announced today that Trevor Royce, MS, MD, MPH, and Sheetal Kircher, MD, have been selected for the ASCO Health Policy Fellowship Program. Now entering its third year, the fellowship program offers oncologists the opportunity to gain the knowledge-base, skills, and experience necessary to shape regulatory and legislative policies that directly affect the practice environment and impact patients with cancer and their care teams.
Alexandria, Va. – An analysis published today in the American Society of Clinical Oncology’s (ASCO) Journal of Oncology Practice (JOP), suggests that including cancer drug costs in bundled payments under Medicare risks destabilizing the cancer care delivery environment. According to the report, Medicare reimbursement would vary widely in such a model depending on the mix of patient conditions practices treat, rather than the quality of care they provide—with reimbursement to practices that see a large volume of complex patients declining significantly from current levels.
The American Society of Clinical Oncology (ASCO) applauds Congress for its bipartisan support of the omnibus spending bill that significantly boosts our nation's investment in biomedical research. By providing a $3 billion funding increase for the National Institutes of Health (NIH) for fiscal year (FY) 2018—the biggest NIH funding increase in 15 years—Congress has taken bold action to regain much-needed momentum in cancer research following a decade of stagnant funding for the NIH.
ASCO Statement on JAMA Internal Medicine’s Cigarette, Cigar, and Pipe Use Mortality Risk Study
Statement from Bruce E. Johnson, MD, FASCO, President of the American Society of Clinical Oncology (ASCO)
The American Society of Clinical Oncology (ASCO) commends Congress for passing a continuing resolution that includes an important correction to the Merit-based Incentive Payment System. We are also pleased to see a budget deal that commits to at least a $2 billion funding increase for the National Institutes of Health (NIH) to reclaim America’s leadership in cancer research and continue building on our tremendous progress towards understanding, preventing, and treating cancer.
The American Society of Clinical Oncology (ASCO) today released its review of leading oncology pathway vendors in the United States. "Oncology Clinical Pathways: Charting the Landscape of Pathway Providers," published in the Journal of Oncology Practice (JOP), examines the clinical pathways offered by six commercial vendors using the society's criteria for high-quality clinical pathways.